cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2024-4132DCYASTcardiovascular-4132Research ArticleСОВЕТ ЭКСПЕРТОВEXPERT CONSENSUSАлгоритм скрининга додементных когнитивных нарушений у пациентов с сердечно-сосудистыми заболеваниями на приеме у терапевта. Консенсус Совета экспертовScreening algorithm for predementia cognitive impairment in cardiovascular patients at a general practitioner's appointment. Expert Consensus Statementhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Д.м.н., профессор, академик РАН, директор ФГБУ «НМИЦ ТПМ» Минздрава России; зав. кафедрой терапии и профилактической медицины ФГБОУ ВО "РУМ" Минздрава России.

Москва

https://orcid.org/0000-0003-1002-1895БернсС. А.BernsS. A.

Д.м.н., профессор, зав. кафедрой терапии и общей врачебной практики.

Москва

svberns@yandex.ruhttps://orcid.org/0000-0002-6968-7627НикулинаС. Ю.NikulinaS. Yu.

Д.м.н., профессор, зав. кафедрой факультетской терапии.

Красноярск

https://orcid.org/0000-0003-1256-2695СоловьеваЭ. Ю.SolovievaE. Yu.

Д.м.н., зав. кафедрой неврологии факультета дополнительного профессионального образования Института непрерывного образования и профессионального развития.

Москва

ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России; ФГБОУ ВО "Российский университет медицины" Минздрава РоссииRussian FederationФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава РоссииRussian FederationКрасГМУ им. проф. В.Ф. Войно-ЯсенецкогоRussian FederationФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России (Пироговский университет)Russian Federation202411092024231041324132Copyright © Драпкина О.М., Бернс С.А., Никулина С.Ю., Соловьева Э.Ю., 20242024Драпкина О.М., Бернс С.А., Никулина С.Ю., Соловьева Э.Ю.Drapkina O.M., Berns S.A., Nikulina S.Y., Solovieva E.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/4132

.

когнитивные нарушениякогнитивные расстройствасердечно-сосудистые заболеваниядодементные когнитивные расстройстваумеренные когнитивные расстройстваcognitive impairmentcognitive disorderscardiovascular di­seasespredementia cognitive impairmentmild cognitive impairmentReferencesБойцов С. А., Самородская И. В. Сердечно-сосудистые заболевания и когнитивные нарушения. Журнал неврологии и психиатрии им. С. С. Корсакова. 2022;122(7):7-13. doi:10.17116/jnevro20221220717.Boytsov SA, Samorodskaya IV. Cardiovascular disease and cognitive impairment. S. S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7):7-13. (In Russ.) doi:10.17116/jnevro20221220717.Самородская И. В., Старинская М. А., Бойцов С. А. Динамика региональных показателей смертности от сердечно-сосудистых заболеваний и когнитивных нарушений в России 2019-2021 годах. Российский кардиологический журнал. 2023;28(4):5256. doi:10.15829/1560-4071-2023-5256.Samorodskaya IV, Starinskaya MA, Boytsov SA. Dynamics of Regional Mortality Rates from Cardiovascular Diseases and Cognitive Impairments in Russia in 2019-2021. Russian Journal of Cardiology. 2023;28(4):5256. (In Russ.) doi:10.15829/1560-4071-2023-5256.Евдокимова А. Г., Стрюк Р. И., Евдокимов В. В. и др. Роль сердечно-сосудистых заболеваний в развитии болезни Альцгеймера и когнитивных нарушений, в том числе при COVID-19. Международный журнал сердца и сосудистых заболеваний. 2023;38(11):5-17. doi:10.24412/2311-1623-2023-38-5-17.Evdokimova AG, Stryuk RI, Evdokimov VV, et al. The role of car­diovascular diseases in the development of Alzheimer's disease and cognitive impairments, including during COVID-19. International Journal of Heart and Vascular Diseases. 2023; 38(11):5-17. (In Russ.) doi:10.24412/2311-1623-2023-38-5-17.Фонякин А. В., Гераскина Л. А., Магомедова А. Р. и др. Сердечно-сосудистые заболевания и нарушение когнитивных функций. Профилактика и лечение. РМЖ. 2011;9:538.Fonyakin AV, Geraskina LA, Magomedova AR, et al. Cardiovascular diseases and cognitive function impairment. Prevention and treatment. RMJ. 2011;9:538. (In Russ.)Симерзин В. В., Фатенков О. В., Панишева Я. А. и др. Возрастные инволютивные особенности когнитивных функций. Наука и инновации в медицине. 2019;4(2):21-6. doi:10.35693/2500-1388-2019-4-2-21-26.Simerzin VV, Fatenkov OV, Panisheva YA, et al. Age-related involutive features of cognitive functions. Science and Innovations in Medicine. 2019;4(2):21-6. (In Russ.) doi:10.35693/2500-1388-2019-4-2-21-26.Petersen RC, Lopez O, Armstrong MJ, et al. Practice guide­line update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126-35. doi:10.1212/WNL.0000000000004826.Petersen RC, Lopez O, Armstrong MJ, et al. Practice guide­line update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126-35. doi:10.1212/WNL.0000000000004826.Левин О. С., Васенина Е. Е., Ганькина О. А. Диагностика и лечение умеренного когнитивного расстройства. Современная терапия в психиатрии и неврологии. 2014;(4):4-9.Levin OS, Vasenina EE, Gankina OA. Diagnosis and treatment of mild cognitive impairment. Modern Therapy in Psychiatry and Neurology. 2014;(4):4-9. (In Russ.)Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60(10): 1385-9. doi:10.1001/archneur.60.10.1385.Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60(10): 1385-9. doi:10.1001/archneur.60.10.1385.Васенина Е. Е., Гуторова Д. А., Смирнова И. М. и др. Додементные когнитивные расстройства: современные подходы к терминологии, диагностике и лечению. Фарматека. 2018; (14):8-16. doi:10.18565/pharmateca.2018.14.8-16.Vasenina EE, Gutorova DA, Smirnova IM, et al. Predementia cog­nitive disorders: modern approaches to terminology, dia­g­nosis and treatment. Pharmateca. 2018;(14):8-16. (In Russ.) doi:10.18565/pharmateca.2018.14.8-16.Jessen F, Wiese B, Bachmann C, et al; German Study on Aging, Cognition and Dementia in Primary Care Patients Study Group. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010;67(4):414-22. doi:10.1001/archgenpsychiatry.2010.30.Jessen F, Wiese B, Bachmann C, et al; German Study on Aging, Cognition and Dementia in Primary Care Patients Study Group. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010;67(4):414-22. doi:10.1001/archgenpsychiatry.2010.30.McCarthy P, Benuskova L, Franz EA. The age-related posterior-anterior shift as revealed by voxelwise analysis of functional brain networks. Front Aging Neurosci. 2014;6:301. doi:10.3389/fnagi.2014.00301.McCarthy P, Benuskova L, Franz EA. The age-related posterior-anterior shift as revealed by voxelwise analysis of functional brain networks. Front Aging Neurosci. 2014;6:301. doi:10.3389/fnagi.2014.00301.Шаварова Е. К., Шаваров А. А., Ахметов Р. Е., Кобалава Ж. Д. Когнитивные нарушения у пациентов кардиологического профиля: диагностика и профилактика. Кардиология и сердечно-сосудистая хирургия. 2022;15(6):560-9. doi:10.17116/kardio202215061560.Shavarova EK, Shavarov AA, Akhmetov RE, Kobalava ZD. Cog­nitive Impairments in Cardiological Patients: Diagnosis and Prevention. Russian Journal of Cardiology and Cardiovascular Surgery. 2022;15(6):560-9. (In Russ.) doi:10.17116/kardio202215061560.Ou YN, Tan CC, Shen XN, et al. Blood pressure and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 209 prospective studies. Hypertension. 2020;76(1):217-25. doi:10.1161/HYPERTENSIONAHA.120.14993.Ou YN, Tan CC, Shen XN, et al. Blood pressure and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 209 prospective studies. Hypertension. 2020;76(1):217-25. doi:10.1161/HYPERTENSIONAHA.120.14993.de Menezes ST, Giatti L, Brant LCC, et al. Hypertension, pre­hypertension, and hypertension control: Association with decline in cognitive performance in the ELSA-Brasil cohort. Hypertension. 2021;77(2):672-81. doi:10.1161/HYPERTENSIONAHA.120.16080.de Menezes ST, Giatti L, Brant LCC, et al. Hypertension, pre­hypertension, and hypertension control: Association with decline in cognitive performance in the ELSA-Brasil cohort. Hypertension. 2021;77(2):672-81. doi:10.1161/HYPERTENSIONAHA.120.16080.Ungvari Z, Toth P, Tarantini S, et al. Hypertension-induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol. 2021;17:639-54. doi:10.1038/s41581-021-00430-6.Ungvari Z, Toth P, Tarantini S, et al. Hypertension-induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol. 2021;17:639-54. doi:10.1038/s41581-021-00430-6.Marzona I, O’Donnell M, Teo K, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ. 2012;184(6):329-36. doi:10.1503/cmaj.111173.Marzona I, O’Donnell M, Teo K, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ. 2012;184(6):329-36. doi:10.1503/cmaj.111173.Liao JN, Chao TF, Liu CJ, et al. Risk and prediction of dementia in patients with atrial fibrillation-a nationwide population-based cohort study. Int J Cardiol. 2015;199:25-30. doi:10.1016/j.ijcard.2015.06.170.Liao JN, Chao TF, Liu CJ, et al. Risk and prediction of dementia in patients with atrial fibrillation-a nationwide population-based cohort study. Int J Cardiol. 2015;199:25-30. doi:10.1016/j.ijcard.2015.06.170.Nagata T, Ohara T, Hata J, et al. NT-proBNP and Risk of Dementia in a General Japanese Elderly Population: The Hisayama Study. J Am Heart Assoc. 2019;8:e011652. doi:10.1161/JAHA.118.011652.Nagata T, Ohara T, Hata J, et al. NT-proBNP and Risk of Dementia in a General Japanese Elderly Population: The Hisayama Study. J Am Heart Assoc. 2019;8:e011652. doi:10.1161/JAHA.118.011652.Lee TC, Qian M, Liu Y, et al. Cognitive Decline Over Time in Patients with Systolic Heart Failure: Insights From WARCEF. JACC Heart Fail. 2019;7:1042-53. doi:10.1016/j.jchf.2019.09.003.Lee TC, Qian M, Liu Y, et al. Cognitive Decline Over Time in Patients with Systolic Heart Failure: Insights From WARCEF. JACC Heart Fail. 2019;7:1042-53. doi:10.1016/j.jchf.2019.09.003.Connors EJ, Hauson AO, Barlet BD, et al. Neuropsychological Assessment and Screening in Heart Failure: a Meta-Analysis and Systematic Review. Neuropsychol Rev. 2021;31(2):312-30. doi:10.1007/s11065-020-09463-3.Connors EJ, Hauson AO, Barlet BD, et al. Neuropsychological Assessment and Screening in Heart Failure: a Meta-Analysis and Systematic Review. Neuropsychol Rev. 2021;31(2):312-30. doi:10.1007/s11065-020-09463-3.Babayigit E, Murat S, Mert KU, et al. Assessment of Cerebral Blood Flow Velocities with Transcranial Doppler Ultrasonography in Heart Failure Patients with Reduced Ejection Fraction. J Stroke Cerebrovasc Dis. 2021;30:105706. doi:10.1016/j.jstrokecerebrovasdis.2021.105706.Babayigit E, Murat S, Mert KU, et al. Assessment of Cerebral Blood Flow Velocities with Transcranial Doppler Ultrasonography in Heart Failure Patients with Reduced Ejection Fraction. J Stroke Cerebrovasc Dis. 2021;30:105706. doi:10.1016/j.jstrokecerebrovasdis.2021.105706.Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.Hawkins MAW, Gathright EC, Gunstad J, et al. The MoCA and MMSE as screeners for cognitive impairment in a heart failure population: A study with comprehensive neuro-psychological testing. Heart Lung. 2014;43:462-8. doi:10.1016/j.hrtlng.2014.05.011.Hawkins MAW, Gathright EC, Gunstad J, et al. The MoCA and MMSE as screeners for cognitive impairment in a heart failure population: A study with comprehensive neuro-psychological testing. Heart Lung. 2014;43:462-8. doi:10.1016/j.hrtlng.2014.05.011.Alagiakrishnan K, Mah D, Dyck JR, et al. Comparison of two commonly used clinical cognitive screening tests to diagnose mild cognitive impairment in heart failure with the golden standard European Consortium Criteria. Int J Cardiol. 2017;228:558-62. doi:10.1016/j.ijcard.2016.11.193.Alagiakrishnan K, Mah D, Dyck JR, et al. Comparison of two commonly used clinical cognitive screening tests to diagnose mild cognitive impairment in heart failure with the golden standard European Consortium Criteria. Int J Cardiol. 2017;228:558-62. doi:10.1016/j.ijcard.2016.11.193.Mormont E, Jamart J, Robaye L. Validity of the five-word test for the evaluation of verbal episodic memory and dementia in a memory clinic setting. J Geriatr Psychiatry Neurol. 2012; 25(2):78-84.Mormont E, Jamart J, Robaye L. Validity of the five-word test for the evaluation of verbal episodic memory and dementia in a memory clinic setting. J Geriatr Psychiatry Neurol. 2012; 25(2):78-84.Nishiwaki Y, Breeze E, Smeeth L, et al. Validity of the Clock-Drawing Test as a screening tool for cognitive impairment in the elderly. Am J Epidemiol. 2004;160(8):797-807.Nishiwaki Y, Breeze E, Smeeth L, et al. Validity of the Clock-Drawing Test as a screening tool for cognitive impairment in the elderly. Am J Epidemiol. 2004;160(8):797-807.Borkowski JG, Benton A, Spreen O. Word fluency and braindamage. Neuropsychologia. 1976;5:135-40.Borkowski JG, Benton A, Spreen O. Word fluency and braindamage. Neuropsychologia. 1976;5:135-40.Borson S, Scanlan JM, Chen PJ, et al. The Mini-Cog as a screen for dementia: Validation in a population-based sample. J Am Geriatr Soc. 2003;51:1451-4.Borson S, Scanlan JM, Chen PJ, et al. The Mini-Cog as a screen for dementia: Validation in a population-based sample. J Am Geriatr Soc. 2003;51:1451-4.Livingston G, Huntley J, Sommerlad A, et al. Dementia pre­vention, intervention, and care: 2020 report of the Lancet Commis­sion. Lancet. 2020;8(396):413-46. doi:10.1016/S0140-6736(20)30367-6.Livingston G, Huntley J, Sommerlad A, et al. Dementia pre­vention, intervention, and care: 2020 report of the Lancet Commis­sion. Lancet. 2020;8(396):413-46. doi:10.1016/S0140-6736(20)30367-6.Стуров Н. В. Применение препарата Ноопепт® при когнитивных нарушениях различного генеза. Трудный пациент. 2012;10(11):28-32.Sturov NV. Use of Noopept® for cognitive impairments of various origins. Difficult Patient. 2012;10(11):28-32. (In Russ.)Zainullina LF, Ivanova TV, Sadovnikov SV, et al. Cognitive Enhancer Noopept Activates Transcription Factor HIF-1. Dokl Biochem Biophys. 2020;494(1):256-60. doi:10.1134/S1607672920050129.Zainullina LF, Ivanova TV, Sadovnikov SV, et al. Cognitive Enhancer Noopept Activates Transcription Factor HIF-1. Dokl Biochem Biophys. 2020;494(1):256-60. doi:10.1134/S1607672920050129.Скребицкий В. Г., Капай Н. А., Деревягин В. И. и др. Действие фармакологических препаратов на синаптическую активность гиппокампа. Анналы клинической и экспериментальной неврологии. 2008;2(2):23-7.Skrebitsky VG, Kapai NA, Derevyagin VI, et al. The effect of pharmacological drugs on the synaptic activity of the hippocampus. Ann Clin Exp Neurol. 2008;2(2):23-7. (In Russ.)Ostrovskaya RU, Gudasheva TA, Zaplina AP, et al. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med. 2008;146(3):334-7. doi:10.1007/s10517-008-0297-x.Ostrovskaya RU, Gudasheva TA, Zaplina AP, et al. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med. 2008;146(3):334-7. doi:10.1007/s10517-008-0297-x.Гаврилова С. И., Колыхалов И. В., Федорова Я. Б. и др. Опыт клинического применения Ноопепта в лечении синдрома мягкого когнитивного снижения. Современная терапия психических расстройств. 2008;(1):27-32. EDN QBRWIZ.Gavrilova SI, Kolykhalov IV, Fedorova YaB, et al. Clinical experience of Noopept in the treatment of mild cognitive decline syndrome. Modern therapy of mental disorders. 2008;(1):27-32. (In Russ.) EDN QBRWIZ.Дадашева М. Н., Горенков Р. В., Круглов В. А. и др. Возможности применения ноотропных препаратов у пациентов с недементными сосудистыми когнитивными нарушениями. Неврология, нейропсихиатрия, психосоматика. 2022;14(2):49-55. doi:10.14412/2074-2711-2022-2-49-55.Dadasheva MN, Gorenkov RV, Kruglov VA, et al. Possibilities of using nootropic drugs in patients with non-dementia vascular cognitive impairments. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(2):49-55. (In Russ.) doi:10.14412/2074-2711-2022-2-49-55.

The authors declare that there are no conflicts of interest present.